Skip navigation

Navigate Medical Affairs Complexities and Shine Light on R&D Compliance to Propel Scientific Exchange

June 15-16, 2017
  • Philadelphia, PA

CBI’s highly acclaimed Compliance Congress on Non-Promotional Activities offers an unparalleled agenda delivered by the industry’s leading experts. During this meeting, navigate medical affairs complexities and shine light on R&D compliance to propel scientific exchange in a time of increased scrutiny. Collaborate with
your peers to zero in on prevailing industry approaches to advance your
company’s compliance efforts and return with clear strategies for
navigating the gray area between clinical and commercial to
ensure compliance enterprise-wide.

CLE, CPE &
CCB Credits
Available! Pending Approval

HOT TOPICS ON THE FOREFRONT:

  • Off-Label Communication — Regulatory Updates and Actions for 2017
  • Keep Pulse on the Latest Enforcement Activities and Areas of Oversight
  • Explore the Evolving Role of Medical Affairs during a Time of Transformative Change
  • Dissemination of Scientific Information — What Does the Future Hold?
  • Zero In on the Fine Line between Commercial and Clinical to Optimize Compliance with Internal Counterparts
  • Enhance Monitoring Efforts to Ensure a Compliant Fleet of MSLs
  • Navigate CME Regulation and Explore Expectations for Industry to Remain Compliant
  • Ramp up Clinical and R&D Oversight to Maintain Compliance
  • Clinical Trial Compliance — Pre, During and Post
  • Examine Compliance Considerations for the Exchange of HEOR and Real-World Evidence
PIONEERING PERSPECTIVES FROM
COMPLIANCE CHANGEMAKERS, INCLUDING:

DAVID CROMLEY
Associate VP,
Global Compliance
Organization
Merck

KYLE FAGET
Senior Corporate
Counsel
Jounce Therapeutics

BRAD GLAZER, BS, PharmD
Head, Medical Governance
and Compliance (MGC),
US Medical Affairs
GlaxoSmithKline

MATT HILL
Senior Director,
Compliance Business
Partners and Training
Novo Nordisk Inc.

PAUL ROWE, MD
Vice President,
Global Medical Affairs,
Head, Respiratory
Sanofi

KRISTI SANFORD
Head, U.S. Medical
Operations and
Global Medical
Affairs Excellence
UCB

SUE SEFERIAN
Global R&D
Health Care
Compliance Officer
Johnson & Johnson

 

SHARE KNOWLEDGE, BENCHMARK BEST PRACTICES
AND BUILD YOUR PROFESSIONAL NETWORK

Full of practical information. Lots of audience participation, which allowed me to really check our practices against others in the industry.

Conference provided useful information that can be leveraged in
day-to-day activities when back in the office.

— ACCLAIM FROM CBI’S COMPLIANCE SERIES

June 15-16, 2017 | DoubleTree Center City | Philadelphia, PA

Bio/Pharma Compliance Congress on Non-Promotional Activities

Navigate Medical Affairs Complexities and Shine Light on R&D Compliance to Propel Scientific Exchange

CBI’s highly acclaimed Compliance Congress on Non-Promotional Activities offers an unparalleled agenda delivered by the industry’s leading experts. During this meeting, navigate medical affairs complexities and shine light on R&D compliance to propel scientific exchange in a time of increased scrutiny. Collaborate with
your peers to zero in on prevailing industry approaches to advance your
company’s compliance efforts and return with clear strategies for
navigating the gray area between clinical and commercial to
ensure compliance enterprise-wide.

CLE, CPE &
CCB Credits
Available! Pending Approval

HOT TOPICS ON THE FOREFRONT:

  • Off-Label Communication — Regulatory Updates and Actions for 2017
  • Keep Pulse on the Latest Enforcement Activities and Areas of Oversight
  • Explore the Evolving Role of Medical Affairs during a Time of Transformative Change
  • Dissemination of Scientific Information — What Does the Future Hold?
  • Zero In on the Fine Line between Commercial and Clinical to Optimize Compliance with Internal Counterparts
  • Enhance Monitoring Efforts to Ensure a Compliant Fleet of MSLs
  • Navigate CME Regulation and Explore Expectations for Industry to Remain Compliant
  • Ramp up Clinical and R&D Oversight to Maintain Compliance
  • Clinical Trial Compliance — Pre, During and Post
  • Examine Compliance Considerations for the Exchange of HEOR and Real-World Evidence
PIONEERING PERSPECTIVES FROM
COMPLIANCE CHANGEMAKERS, INCLUDING:

DAVID CROMLEY
Associate VP,
Global Compliance
Organization
Merck

KYLE FAGET
Senior Corporate
Counsel
Jounce Therapeutics

BRAD GLAZER, BS, PharmD
Head, Medical Governance
and Compliance (MGC),
US Medical Affairs
GlaxoSmithKline

MATT HILL
Senior Director,
Compliance Business
Partners and Training
Novo Nordisk Inc.

PAUL ROWE, MD
Vice President,
Global Medical Affairs,
Head, Respiratory
Sanofi

KRISTI SANFORD
Head, U.S. Medical
Operations and
Global Medical
Affairs Excellence
UCB

SUE SEFERIAN
Global R&D
Health Care
Compliance Officer
Johnson & Johnson

 

SHARE KNOWLEDGE, BENCHMARK BEST PRACTICES
AND BUILD YOUR PROFESSIONAL NETWORK

Full of practical information. Lots of audience participation, which allowed me to really check our practices against others in the industry.

Conference provided useful information that can be leveraged in
day-to-day activities when back in the office.

— ACCLAIM FROM CBI’S COMPLIANCE SERIES

June 15-16, 2017 | DoubleTree Center City | Philadelphia, PA